Can-Fite BioPharma Ltd. CANF
1.66 USD -0.02 (-1.19%)
At closeNov 11, 2026, 4:04 AM EST
1.66 0.00 0.00%
Pre-market · Nov 11, 4:04 AM ET
1.63 Day range 1.69
1.50 52-week range 12.40
- YTD
- -58.50%
- 1 year
- -79.76%
News
benzinga.com Can-Fite Announces 10-Yr Cancer-Free Survival In Advanced Liver Cancer Patient Treated With Namodenoson Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestoneRamat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma…
globenewswire.com Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study Patient from the Company's completed Phase II study remains cancer-free and in good health at the ten-year survival milestone Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma…
benzinga.com Can-Fite Biopharma To Pursue Global Licensing And Strategic Partnerships Using Its Phase IIa Pancreatic Cancer Results Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its…
globenewswire.com Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones Company to leverage positive Phase IIa pancreatic cancer results presented at ESMO 2026, two pivotal Phase III programs, and expanding patent protection to advance global partnering opportunities
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com Can-Fite BioPharma Says EAPO Issues Notification Of Readiness To Grant Patent Covering Use Of Piclidenoson For Treatment Of Diseases Associated With OCRL Deficiency Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione TelethonRamat…
benzinga.com Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months…